Vallejo J, Torres-Avisbal M, Contreras P, Rodríguez-Liñán M, Rebollo A, González F, Benítez A, Infante J, Mateo A
Servicio de Medicina Nuclear, Hospital Universitario Reina Sofía, Córdoba, 14080, España.
Rev Esp Med Nucl. 1999 Aug;18(4):281-6.
The aim of this study was to assess the utility of determining serum levels of the CEA, CA 19.9 and CA 195 tumor markers in 906 patients with colorectal carcinoma for a 5-year follow-up period. In addition to calculating sensitivity and specificity for the common normal limits, the results were analyzed with RO curves. Sensitivity values for 90% and 95% specificity were also obtained. The results of the areas under the curve (CEA: 0.887; CA 19.9: 0.802; CA 195: 0.971) and sensitivities and specificities at different normality limits showed better behavior for CEA with respect to CA 19.9 and CA 195, the last two presenting similar results. CEA continues to be the best tumor marker to monitor patients with colorectal carcinoma.
本研究的目的是评估在906例结直肠癌患者中测定血清癌胚抗原（CEA）、糖类抗原19.9（CA 19.9）和糖类抗原195（CA 195）肿瘤标志物水平用于5年随访期的效用。除了计算常见正常范围的敏感性和特异性外，还用ROC曲线分析结果。还获得了90%和95%特异性时的敏感性值。曲线下面积（CEA：0.887；CA 19.9：0.802；CA 195：0.971）以及不同正常范围时的敏感性和特异性结果显示，CEA相对于CA 19.9和CA 195表现更好，后两者结果相似。CEA仍然是监测结直肠癌患者的最佳肿瘤标志物。
